Cemdomespib (KU-596) is a highly bioavailable second-generationHsp90modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib inducesHsp70levels and manifest neuroprotective activity through induction of the heat shock response^[1][2][3].

After 8 weeks of diabetes, Cemdomespib (KU-596; 2, 10, or 20 mg/kg ; i.p.; administered for 6 weeks via a once per week) dose-dependently reverses the pre-existing psychosensory deficits. Cemdomespib also dose-dependently prevents the diabetes-induced deficits in motor (MNCV) and sensory (SNCV) nerve conduction velocities^[1].
Cemdomespib (20 mg/kg; oral gavage once per week for 4 weeks) significantly reverses the sensory hypoalgesia in WT mice but not the Hsp70 KO mice^[1].

447.50

C₂₄H₃₀FNO₆

1450642-92-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 1.

  Cemdomespib (KU-596) is prepared in 0.1 M Captisol (β-cyclodextrin sulfobutylethers)^[1].